Supernus Pharmaceuticals Company Profile (NASDAQ:SUPN)

About Supernus Pharmaceuticals

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). Its psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. It markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: SUPN
  • CUSIP: 86845910
Key Metrics:
  • Previous Close: $25.35
  • 50 Day Moving Average: $25.55
  • 200 Day Moving Average: $23.49
  • 52-Week Range: $12.15 - $27.95
  • Trailing P/E Ratio: 15.69
  • Foreward P/E Ratio: 20.08
  • P/E Growth: 0.46
  • Market Cap: $1.27B
  • Outstanding Shares: 50,121,000
  • Beta: 1.89
Profitability:
  • Net Margins: 43.38%
  • Return on Equity: 35.33%
  • Return on Assets: 18.67%
Debt:
  • Debt-to-Equity Ratio: 0.03%
  • Current Ratio: 1.93%
  • Quick Ratio: 1.69%
Additional Links:
Companies Related to Supernus Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Supernus Pharmaceuticals (NASDAQ:SUPN) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $26.75 (5.73% upside)

Analysts' Ratings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Show:
DateFirmActionRatingPrice TargetDetails
1/12/2017Cantor FitzgeraldReiterated RatingBuy$32.00View Rating Details
11/16/2016Jefferies Group LLCReiterated RatingBuyView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00View Rating Details
7/18/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$23.00View Rating Details
6/18/2015Stifel NicolausBoost Price TargetBuy$15.00 -> $22.00View Rating Details
6/12/2015SunTrust Banks, Inc.Initiated CoverageBuy$30.00View Rating Details
6/9/2015GuggenheimInitiated CoverageBuy$21.00View Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017        
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)
Current Year EPS Consensus Estimate: $1.45 EPS
Next Year EPS Consensus Estimate: $1.26 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163$0.06$0.10$0.08
Q2 20162$0.13$0.13$0.13
Q3 20162$0.19$0.34$0.27
Q4 20162$0.23$0.30$0.27
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Supernus Pharmaceuticals (NASDAQ:SUPN)
Insider Ownership Percentage: 6.10%
Institutional Ownership Percentage: 94.94%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.00View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.38View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.20View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.65View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.00View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.00View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.85View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Supernus Pharmaceuticals (NASDAQ:SUPN)
DateHeadline
4-traders.com logoSupernus Pharmaceuticals Inc : annual earnings release (NASDAQ:SUPN)
www.4-traders.com - February 23 at 9:01 PM
News IconWhat The Charts Are Saying About Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Searcy News (NASDAQ:SUPN)
searcysentinel.com - February 22 at 8:17 PM
News IconWhat is the Street Saying About Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)? - Aiken Advocate (NASDAQ:SUPN)
aikenadvocate.com - February 22 at 8:17 PM
News IconSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Price Target Set At $29.6 - Transcript Daily (NASDAQ:SUPN)
transcriptdaily.com - February 22 at 8:17 PM
News IconSupernus files form 10-q for third quarter 2016 and is now current with all financial filings – forextv (NASDAQ:SUPN)
getthatmoneyhoney.com - February 17 at 7:19 PM
4-traders.com logoSUPERNUS PHARMACEUTICALS INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:SUPN)
www.4-traders.com - February 16 at 7:50 PM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:SUPN)
biz.yahoo.com - February 16 at 7:50 PM
globenewswire.com logoSupernus to Host Fourth Quarter and Full Year 2016 Earnings ... - GlobeNewswire (press release) (NASDAQ:SUPN)
globenewswire.com - February 13 at 8:27 PM
finance.yahoo.com logoSupernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call (NASDAQ:SUPN)
finance.yahoo.com - February 13 at 8:27 PM
News IconEquity Check-in on Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - The Standard (NASDAQ:SUPN)
6milestandard.com - February 13 at 3:26 PM
marketexclusive.com logoSupernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Other Events - Market Exclusive (NASDAQ:SUPN)
marketexclusive.com - February 13 at 1:00 AM
us.rd.yahoo.com logoSupernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR® (NASDAQ:SUPN)
us.rd.yahoo.com - February 9 at 5:37 AM
News IconNDX Closes at the High for the Day (NASDAQ:SUPN)
www.fxstreet.com - February 7 at 1:11 AM
streetinsider.com logoSupernus Pharma (SUPN) Reports Seventh U.S. Patent Protecting Trokendi XR - StreetInsider.com (NASDAQ:SUPN)
www.streetinsider.com - February 1 at 6:44 AM
streetinsider.com logoSupernus Pharma (SUPN) Reports Seventh U.S. Patent Protecting Trokendi XR (NASDAQ:SUPN)
www.streetinsider.com - January 30 at 12:11 PM
finance.yahoo.com logoSupernus Announces Issuance of Seventh U.S. Patent Protecting Trokendi XR® (NASDAQ:SUPN)
finance.yahoo.com - January 30 at 12:11 PM
finance.yahoo.com logo7:01 am Supernus Pharma announces USPTO issuance of the 7th patent covering Trokendi XR; patent provides protection for the product with expiration that is no earlier than 2027 (NASDAQ:SUPN)
finance.yahoo.com - January 30 at 12:11 PM
seekingalpha.com logoSupernus Is Moving In The Right Direction - Seeking Alpha (NASDAQ:SUPN)
seekingalpha.com - January 27 at 5:34 AM
News IconRelative Strength Index Check on Supernus Pharmaceuticals Inc. (SUPN) - Market Point (NASDAQ:SUPN)
mtptnews.com - January 27 at 5:34 AM
News IconHealthinvest Partners Ab Boosts Position by $13294553 in Supernus Pharmaceuticals Inc (SUPN) - Highland Mirror (NASDAQ:SUPN)
www.highlandmirror.com - January 27 at 5:34 AM
finance.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Financials (NASDAQ:SUPN)
finance.yahoo.com - January 27 at 5:34 AM
4-traders.com logoSupernus Pharmaceuticals,Inc. (NASDAQ:SUPN) Files An 8-K Regulation FD Disclosure (NASDAQ:SUPN)
www.4-traders.com - January 26 at 6:06 AM
finance.yahoo.com logoSupernus Files Form 10-Q for Third Quarter 2016 and Is Now Current with All Financial Filings (NASDAQ:SUPN)
finance.yahoo.com - January 23 at 10:48 PM
capitalcube.com logoSupernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : January 23, 2017 (NASDAQ:SUPN)
www.capitalcube.com - January 23 at 10:48 PM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:SUPN)
biz.yahoo.com - January 23 at 10:48 PM
News IconSupernus Pharmaceuticals Inc SUPN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SUPN)
www.bioportfolio.com - January 21 at 7:48 PM
capitalcube.com logoSupernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : SUPN-US : January 20, 2017 (NASDAQ:SUPN)
us.rd.yahoo.com - January 21 at 2:24 AM
biz.yahoo.com logoSUPERNUS PHARMACEUTICALS INC Files SEC form 10-Q/A, Quarterly Report (NASDAQ:SUPN)
us.rd.yahoo.com - January 21 at 2:24 AM
sg.finance.yahoo.com logoSupernus misses 3Q revenue forecasts (NASDAQ:SUPN)
sg.finance.yahoo.com - January 21 at 2:24 AM
News IconEPS Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) At $0.23 - Stock Observer (NASDAQ:SUPN)
www.thestockobserver.com - January 15 at 7:31 PM
News IconMarket Scope: Taking a Look at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Beacon (NASDAQ:SUPN)
wsbeacon.com - January 8 at 8:04 PM
News IconShould You Expect Supernus Pharmaceuticals Inc (SUPN) To Deliver A Superior ROE To Its Industry? (NASDAQ:SUPN)
simplywall.st - January 5 at 6:53 AM
finance.yahoo.com logoSupernus to Present at the 2017 J.P. Morgan Healthcare Conference (NASDAQ:SUPN)
finance.yahoo.com - January 4 at 5:17 AM
News IconSupernus Pharmaceuticals, Inc. (NASDAQ:SUPN) News Impact Score At 90 - Stock Observer (NASDAQ:SUPN)
www.thestockobserver.com - December 30 at 10:10 PM
News IconLevels in View for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Beacon (NASDAQ:SUPN)
wsbeacon.com - December 30 at 10:10 PM
nasdaq.com logoCommit To Buy Supernus Pharmaceuticals At $20, Earn 10.7% Annualized Using Options (NASDAQ:SUPN)
www.nasdaq.com - December 29 at 8:00 PM
nasdaq.com logoCommit To Buy Supernus Pharmaceuticals At $20, Earn 10.7% Annualized Using Options - Nasdaq (NASDAQ:SUPN)
www.nasdaq.com - December 28 at 7:53 PM
News IconNews Impact Score Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) At 50 - Stock Observer (NASDAQ:SUPN)
www.thestockobserver.com - December 23 at 8:08 PM
News IconStock Spotlight: Checking on Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Beacon (NASDAQ:SUPN)
wsbeacon.com - December 23 at 8:08 PM
News IconInvestor Focus: Watching Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Wall Street Beacon (NASDAQ:SUPN)
wsbeacon.com - December 22 at 3:23 AM
News IconInvestor Update: Tracking Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - The Business Journal (NASDAQ:SUPN)
belmontbusinessjournal.com - December 21 at 1:05 AM
News IconMarket Corner: Eye on Technicals for Supernus Pharmaceuticals Inc. (SUPN) - StockTalk Daily (NASDAQ:SUPN)
stocktalkdaily.com - December 20 at 7:57 PM
News IconMF Rank Review for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Business Daily Leader (NASDAQ:SUPN)
businessdailyleader.com - December 20 at 7:57 PM
thestreet.com logoThe Bulls Don't Have Enough Juice for 20,000 (NASDAQ:SUPN)
realmoney.thestreet.com - December 20 at 2:55 PM
News IconCompany Stock Focus on Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - OIB News (NASDAQ:SUPN)
oibnews.com - December 19 at 11:05 AM
insidermonkey.com logoIs Precision Drilling Corp (USA) (PDS) A Good Stock To Buy? (NASDAQ:SUPN)
www.insidermonkey.com - December 18 at 11:19 PM
marketexclusive.com logoAnalyst Activity – Cantor Fitzgerald Initiates Coverage On Supernus Pharmaceuticals (NASDAQ:SUPN) With a Overweight (NASDAQ:SUPN)
marketexclusive.com - December 17 at 2:21 AM
News IconKeeping Tabs on Levels for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - The Business Journal (NASDAQ:SUPN)
belmontbusinessjournal.com - December 16 at 5:09 AM
News IconInvestor Update: Looking at Shares of Supernus Pharmaceuticals ... - Wall Street Beacon (NASDAQ:SUPN)
wsbeacon.com - December 16 at 5:09 AM
seekingalpha.com logoSupernus Pharmaceuticals: The Investment Case Improves ... - Seeking Alpha (NASDAQ:SUPN)
seekingalpha.com - December 16 at 5:09 AM

Social

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 1-year price objectives for Supernus Pharmaceuticals' shares. Their forecasts range from $23.00 to $32.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $26.75 in the next year.

When will Supernus Pharmaceuticals announce their earnings?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

What are analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (2/4/2017)

  • Cantor Fitzgerald analysts commented, "SUPN still trying to reach agreement with generic challengers. Based on a recent conversation with management, we understand that the company will continue to try and reach a settlement with Actavis and Zydus regarding infringement of patents related to Trokendi XR. We believe the judge in the case would prefer the companies reach a settlement vs. advance to a court trial." (1/12/2017)

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ranger Investment Management L.P. (2.88%), State Street Corp (2.60%), Dimensional Fund Advisors LP (2.21%), Fiera Capital Corp (2.18%), Russell Investments Group Ltd. (1.71%) and Neumeier Poma Investment Counsel LLC (1.55%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Jones W Bryan, M James Barrett, Padmanabh P Bhatt, Scott D Sandell and Stefan KF Schwabe.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Neumeier Poma Investment Counsel LLC, Fiera Capital Corp, Oxford Asset Management, Allianz Asset Management AG, Guggenheim Capital LLC, Ranger Investment Management L.P. and Menta Capital LLC. Company insiders that have sold Supernus Pharmaceuticals stock in the last year include Gregory S Patrick and Padmanabh P Bhatt.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Axiom International Investors LLC DE, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, State Street Corp, Trexquant Investment LP, Holderness Investments Co. and Tudor Investment Corp Et Al.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Supernus Pharmaceuticals stock cost?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $25.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Earnings History Chart

Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Dividend History Chart

Dividend Payments by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Last Updated on 2/25/2017 by MarketBeat.com Staff